Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVADEX with ECP in Pediatric Steroid-Refractory aGvHD
NCT02524847Phase 3Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of methoxsalen in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at 4 weeks. Started Jan 2016; status: terminated.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02524847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524847.